123 related articles for article (PubMed ID: 11956087)
1. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
Lentzsch S; Rogers MS; LeBlanc R; Birsner AE; Shah JH; Treston AM; Anderson KC; D'Amato RJ
Cancer Res; 2002 Apr; 62(8):2300-5. PubMed ID: 11956087
[TBL] [Abstract][Full Text] [Related]
2. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
Ojo-Amaize EA; Nchekwube EJ; Cottam HB; Bai R; Verdier-Pinard P; Kakkanaiah VN; Varner JA; Leoni L; Okogun JI; Adesomoju AA; Oyemade OA; Hamel E
Cancer Res; 2002 Jul; 62(14):4007-14. PubMed ID: 12124334
[TBL] [Abstract][Full Text] [Related]
3. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis.
Du GJ; Lin HH; Xu QT; Wang MW
Vascul Pharmacol; 2005 Aug; 43(2):112-9. PubMed ID: 15982930
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
LeBlanc R; Catley LP; Hideshima T; Lentzsch S; Mitsiades CS; Mitsiades N; Neuberg D; Goloubeva O; Pien CS; Adams J; Gupta D; Richardson PG; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):4996-5000. PubMed ID: 12208752
[TBL] [Abstract][Full Text] [Related]
6. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
7. The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway.
DeCicco KL; Tanaka T; Andreola F; De Luca LM
Carcinogenesis; 2004 Oct; 25(10):1805-12. PubMed ID: 15205358
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
9. Generation of multiple angiogenesis inhibitors by human pancreatic cancer.
Kisker O; Onizuka S; Banyard J; Komiyama T; Becker CM; Achilles EG; Barnes CM; O'Reilly MS; Folkman J; Pirie-Shepherd SR
Cancer Res; 2001 Oct; 61(19):7298-304. PubMed ID: 11585769
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
11. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
13. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.
Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling DI; Dalgleish AG
Cancer Res; 2003 Feb; 63(3):593-9. PubMed ID: 12566301
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
16. Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma.
Liu S; Ishikawa H; Li FJ; Ma Z; Otsuyama K; Asaoku H; Abroun S; Zheng X; Tsuyama N; Obata M; Kawano MM
Cancer Res; 2005 Mar; 65(6):2269-76. PubMed ID: 15781640
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tumor growth by plasminogen-related protein-B.
Lewis VO; O'Reilly MS; Gehrmann M; Llinás M; Schaller J; Weissbach L
Anticancer Res; 2001; 21(4A):2287-91. PubMed ID: 11724284
[TBL] [Abstract][Full Text] [Related]
18. Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: possible anti-myeloma mechanism of thalidomide.
Iguchi T; Yachide-Noguchi T; Hashimoto Y; Nakazato S; Sagawa M; Ikeda Y; Kizaki M
Int J Mol Med; 2008 Feb; 21(2):163-8. PubMed ID: 18204782
[TBL] [Abstract][Full Text] [Related]
19. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Mitsiades CS; Ocio EM; Pandiella A; Maiso P; Gajate C; Garayoa M; Vilanova D; Montero JC; Mitsiades N; McMullan CJ; Munshi NC; Hideshima T; Chauhan D; Aviles P; Otero G; Faircloth G; Mateos MV; Richardson PG; Mollinedo F; San-Miguel JF; Anderson KC
Cancer Res; 2008 Jul; 68(13):5216-25. PubMed ID: 18593922
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
Ng SS; Gütschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD
Cancer Res; 2003 Jun; 63(12):3189-94. PubMed ID: 12810647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]